Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients With Castrate Resistant Metastatic Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2019
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 20 Jun 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 31 Aug 2018 Biomarkers information updated
- 11 Dec 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.